-
公开(公告)号:WO2023076096A1
公开(公告)日:2023-05-04
申请号:PCT/US2022/047254
申请日:2022-10-20
发明人: CHUGH, Sumant, Singh
摘要: The invention provides novel approaches to the prevention and treatment of the respiratory or non-respiratory infections and effects of mild to severe cytokine storms including multiorgan effects as well as the reduction in mortality. More particularly, the invention describes specific combinations or cytokines or soluble receptors that must be depleted to eliminate or reduce mortality as the result of severe viral cytokine storms.
-
公开(公告)号:WO2023063453A1
公开(公告)日:2023-04-20
申请号:PCT/KR2021/014331
申请日:2021-10-15
申请人: 주식회사 마이크로바이오틱스
IPC分类号: C12N7/00 , A01N63/40 , A61K35/76 , A61P31/00 , A23L33/135 , A23K10/16 , A23K20/195
摘要: 본 발명은 항생제에 내성을 나타내는 슈도모나스 균속을 용균시키는 박테리오파지에 관한 것이다. 구체적으로, 상기 슈도모나스 균속은 녹농균 (Pseudomonas aeruginosa)에 관한 것일 수 있다.
-
3.
公开(公告)号:WO2023062328A1
公开(公告)日:2023-04-20
申请号:PCT/FR2022/051939
申请日:2022-10-14
IPC分类号: C12N1/04 , C12N1/16 , C12N7/00 , A23L29/00 , A21D8/04 , A61K35/66 , C12G1/00 , A21D10/00 , A61K35/76 , C12R1/865
摘要: La présente demande concerne un procédé de fabrication d'un mélange sec d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage, ledit mélange se présentant sous forme d'entités solides, chaque entité solide consistant en au moins une levure et/ou au moins un dérivé de levure et au moins un bactériophage et éventuellement au moins un excipient de séchage, ledit procédé étant caractérisé en ce qu'il est effectué par le mélange d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage en suspension et le séchage de ce mélange. Elle concerne également un mélange sec d'au moins une levure et/ou d'un dérivé de levure et d'au moins un bactériophage, caractérisé en ce qu'il se présente sous forme d'entités solides, chaque entité solide consistant en au moins une levure et/ou au moins un dérivé de levure et au moins un bactériophage et éventuellement au moins un excipient de séchage et ses utilisations.
-
公开(公告)号:WO2023009622A1
公开(公告)日:2023-02-02
申请号:PCT/US2022/038520
申请日:2022-07-27
摘要: Disclosed herein is a nucleic acid stuffer sequence comprising one or more of the following features: no CPG island and no more than four contiguous nucleobases of the same identity; wherein the nucleic acid stuffer sequences does not include an open reading frame greater than 20 amino acids in length. In some embodiments, the nucleic acid stuffer sequence comprises between about 40% and about 50% GC content. In some embodiments, the nucleic acid stuffer sequence does not comprise a restriction enzyme cleavage site. In some embodiments, the nucleic acid stuffer sequence has a length of about 100 nucleobases to about 5000 nucleobases.
-
5.
公开(公告)号:WO2023288184A2
公开(公告)日:2023-01-19
申请号:PCT/US2022/073560
申请日:2022-07-08
发明人: CHEN, Xiaoke , WANG, Qian , NACHTRAB, Greg
IPC分类号: A61K35/76 , C07K14/015 , C12N15/86 , A61K9/19 , A61K38/17 , A61P25/28 , C07K14/75 , A61K35/761 , A61K38/177 , A61K48/0075 , C07K14/705 , A01K2207/15 , A01K2217/072 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/02 , A01K67/0275 , A61K38/00 , A61K48/005 , A61P1/00 , C07K14/005 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/32 , C12N2330/51 , C12N2750/14122 , C12N2750/14143 , C12N2750/14145
摘要: Methods and compositions are provided for treating an individual in need (e.g., one who has chronic pain). Such methods can include a step of administering a therapy that reduces CamKv activity in opioid receptor mu 1 (OPRM1) expressing neurons of the individual's rostral ventromedial medulla (RVM). In some cases, the therapy (e.g., deep brain stimulation of zona incerta neurons) increases inhibitory input into the individual's RVM. In some cases, the therapy is an agent (e.g., an RNAi agent) that reduces expression or activity of CamKv in the individual's RVM. In some cases, the agent includes a retrograde-enhanced recombinant AAV particle, e.g., one that can be used to deliver an RNAi agent such as an shRNA that targets CamKv. Also provide are retrograde-enhanced clade E variant AAV capsid proteins, AVV particles that include such capsid proteins, methods of making such AAV particles, and methods of expressing a transgene using such AAVs.
-
公开(公告)号:WO2023284597A1
公开(公告)日:2023-01-19
申请号:PCT/CN2022/104040
申请日:2022-07-06
申请人: 杭州阿诺生物医药科技有限公司
IPC分类号: A61K31/5377 , A61K35/76 , A61K39/395 , A61P35/00
摘要: 本申请提供了一种在有此需要的对象中治疗肿瘤/癌症和/或产生针对肿瘤/癌症的记忆免疫应答的方法,包括向所述对象施用有效量的PI3K抑制剂、溶瘤病毒以及PD-1抑制剂,其中,所述PI3K抑制剂、溶瘤病毒和PD-1抑制剂可以同时、分开或者顺序施用。本申请还提供一种包含PI3K抑制剂、溶瘤病毒和PD-1抑制剂、以及可药用载体的药物组合物,以及一种包含所述药物组合物和使用说明的药盒。
-
7.
公开(公告)号:WO2022261498A1
公开(公告)日:2022-12-15
申请号:PCT/US2022/033106
申请日:2022-06-10
发明人: IZADJOO, Mina , KIM, Hosan , IZADJOO, Salman
摘要: Recombinantly-modified Cutibacterium acnes- specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.
-
8.
公开(公告)号:WO2022246030A1
公开(公告)日:2022-11-24
申请号:PCT/US2022/029974
申请日:2022-05-19
申请人: MEMORIAL SLOAN-KETTERING CANCER CENTER , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
发明人: DAO, Tao , SCHEINBERG, David A. , BALDERES, Paul , POHL, Mary Ann
IPC分类号: A61K35/76 , A61K38/16 , A61K39/395 , A61P35/00 , A61P35/02 , C07K14/47 , C07K16/00 , C07K16/28
摘要: The present technology relates generally to compositions that specifically recognize and bind to a serine-phosphorylated IRS2 (pIRS2) peptide RVA[pS]PTSGVK (SEQ ID NO: 19) complexed with a major histocompatability antigen (e.g., HLA-A*02). The compositions of the present technology are useful in methods for treating pIRS2-associated diseases (e.g., cancers) in a subject in need thereof.
-
公开(公告)号:WO2022245919A1
公开(公告)日:2022-11-24
申请号:PCT/US2022/029797
申请日:2022-05-18
发明人: PADEGIMAS, Linas , KEVANY, Brian
IPC分类号: A61K35/76 , A61P27/02 , C12N15/35 , C12N15/864
摘要: Provided herein are recombinant AAV vectors, AAV viral vectors, capsid proteins, and administration methods for improved gene therapy, and methods for their manufacture and use.
-
公开(公告)号:WO2022239863A1
公开(公告)日:2022-11-17
申请号:PCT/JP2022/020224
申请日:2022-05-13
申请人: 国立大学法人千葉大学
IPC分类号: A61K48/00 , A61P3/06 , A61P3/10 , A61P9/10 , A61P27/12 , A61P43/00 , A61P17/00 , A61P17/14 , C12N15/113 , C12N15/86 , A61K35/76 , A61K31/7088
摘要: 本発明は、ウェルナー症候群を直接的な変異遺伝子の修復を介さず治療できるアンチセンスオリゴマー又はその薬学的に許容される塩を提供することを課題とする。 本発明は、下記(i)又は(ii)の塩基配列に相補的な塩基配列からなり、ヒトWRN遺伝子の第27番目のエクソンのスキッピングを可能とする、アンチセンスオリゴマー又はその薬学的に許容される塩を提供する。 (i)配列番号1に示す塩基配列のうち15塩基以上の連続した塩基配列 (ii)配列番号1に示す塩基配列のうち15塩基以上の連続した塩基配列において、1又は複数の塩基が欠失、置換又は挿入された塩基配列
-
-
-
-
-
-
-
-
-